Journal: International Journal of Inflammation

Article Title: NPT1220-312, a TLR2/TLR9 Small Molecule Antagonist, Inhibits Pro-Inflammatory Signaling, Cytokine Release, and NLRP3 Inflammasome Activation

doi: 10.1155/2022/2337363

Figure Lengend Snippet: NPT1220-312 selectively inhibits TLR2 and TLR9. NPT1220-312 inhibition of (a) TLR1/2 as activated by Pam 3 CSK 4 and TLR2/6 as activated by Pam 2 CSK 4 in HEK293 cells overexpressing hTLR2; (b) TLR3 as activated by Poly I:C in HEK293 cells overexpressing hTLR3; (c) TLR4 as activated by LPS in HEK293 cells overexpressing hTLR4; (d) TLR7 as activated by R848 and as activated by CL-264 in HEK293 cells overexpressing hTLR7; (e) TLR8 as activated by R848 in HEK293 cells overexpressing hTLR8; and (f) TLR9 as activated by ODN2006 in HEK293 cells overexpressing hTLR9. TNF α was incorporated as a control for non-specific inhibition of signaling in each assay.

Article Snippet: The growth medium was supplemented with antibiotics, 1x HEK-Blue Selection for hTLR2 or hTLR4 cells, 30 μ g/ml blasiticidin and 100 μ g/ml zeocin for hTLR3, and hTLR8 cells, 10 μ g/ml blasticidin and 100 μ g/ml zeocin for hTLR7 and hTLR9 cells, and 10 μ g/ml blasticidin for murine RAW-Blue cells (InvivoGen).

Techniques: Inhibition, Control